HRP20110624T1 - Supstituirani piperazinilpirazini kao antagonisti receptora 5-ht7 - Google Patents
Supstituirani piperazinilpirazini kao antagonisti receptora 5-ht7 Download PDFInfo
- Publication number
- HRP20110624T1 HRP20110624T1 HR20110624T HRP20110624T HRP20110624T1 HR P20110624 T1 HRP20110624 T1 HR P20110624T1 HR 20110624 T HR20110624 T HR 20110624T HR P20110624 T HRP20110624 T HR P20110624T HR P20110624 T1 HRP20110624 T1 HR P20110624T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- pharmaceutically acceptable
- acceptable salt
- fluorine
- methyl
- Prior art date
Links
- HCGFLVDMFDHYJD-UHFFFAOYSA-N 2-piperazin-1-ylpyrazine Chemical class C1CNCCN1C1=CN=CC=N1 HCGFLVDMFDHYJD-UHFFFAOYSA-N 0.000 title 1
- 108091005436 5-HT7 receptors Proteins 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 19
- -1 pyrazol-4-yl Chemical group 0.000 claims abstract 17
- 150000003839 salts Chemical class 0.000 claims abstract 15
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 12
- 239000011737 fluorine Substances 0.000 claims abstract 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract 9
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 9
- 239000000460 chlorine Substances 0.000 claims abstract 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 9
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 6
- 239000001257 hydrogen Substances 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 5
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 5
- 150000002431 hydrogen Chemical group 0.000 claims abstract 4
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract 2
- 125000001544 thienyl group Chemical group 0.000 claims abstract 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Spoj formule: naznačen time što: A je -C(H)= ili -N=,R1 se bira iz skupine koju čine fenil, izborno supstituiran s metoksi ili 1 do 3 neovisno odabrana supstituenta, klora ili fluora; pirazol-4-il, izborno supstituiran s 1 do 3 metilne ili etilne skupine; imidazolil, izborno supstituiran s 1 ili 2 metila ili etila; piridil, izborno supstituiran s fluorom ili klorom; te tienil; R2 je vodik ili metil; m je 0, 1 ili 2; R3 se bira iz skupine koju čine vodik, fluor, klor, hidroksi, metoksi, hidroksimetil, cijanometil, metoksimetil, acetil, metilkarbonilamino, metilkarbonilaminometil, pirazol-1-ilmetil i triazolilmetil, uz uvjet da kada R3 je vodik, m nije 0; svaki R4 se neovisno bira iz skupine koju čine fluor, klor, metil i metoksi; ili su, alternativno, dvije skupine R4, zajedno s fenilom na kojeg su vezane, povezane u indol-4-ilnu skupinu; ili njegova farmaceutski prihvatljiva sol. Patent sadrži još 17 patentnih zahtjeva.
Claims (18)
1. Spoj formule:
[image]
naznačen time što:
A je -C(H)= ili -N=,
R1 se bira iz skupine koju čine fenil, izborno supstituiran s metoksi ili 1 do 3 neovisno odabrana supstituenta, klora ili fluora; pirazol-4-il, izborno supstituiran s 1 do 3 metilne ili etilne skupine; imidazolil, izborno supstituiran s 1 ili 2 metila ili etila; piridil, izborno supstituiran s fluorom ili klorom; te tienil;
R2 je vodik ili metil;
m je 0, 1 ili 2;
R3 se bira iz skupine koju čine vodik, fluor, klor, hidroksi, metoksi, hidroksimetil, cijanometil, metoksimetil, acetil, metilkarbonilamino, metilkarbonilaminometil, pirazol-1-ilmetil i triazolilmetil, uz uvjet da kada R3 je vodik, m nije 0;
svaki R4 se neovisno bira iz skupine koju čine fluor, klor, metil i metoksi; ili su, alternativno, dvije skupine R4, zajedno s fenilom na kojeg su vezane, povezane u indol-4-ilnu skupinu;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što A je -N=; ili njegova farmaceutski prihvatljiva sol.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što A je -CH=; ili njegova farmaceutski prihvatljiva sol.
4. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 3, naznačen time što R1 je fenil, izborno supstituiran s metoksi ili s 1 do 3 neovisno odabrana supstituenta, klora ili fluora; ili njegova farmaceutski prihvatljiva sol.
5. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 3, naznačen time što R1 je pirazol-4-il, izborno supstituiran s 1 do 3 metilne ili etilne skupine; ili njegova farmaceutski prihvatljiva sol.
6. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 3, naznačen time što R1 je imidazolil, izborno supstituiran s 1 ili 2 metila ili etila; ili njegova farmaceutski prihvatljiva sol.
7. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 3, naznačen time što R1 je piridil, izborno supstituiran s fluorom ili klorom; ili njegova farmaceutski prihvatljiva sol.
8. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 3, naznačen time što R1 je tienil; ili njegova farmaceutski prihvatljiva sol.
9. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 8, naznačen time što R3 je fluor, hidroksimetil, metoksimetil ili cijanometil; ili njegova farmaceutski prihvatljiva sol.
10. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 8, naznačen time što R3 je fluor ili metoksimetil; ili njegova farmaceutski prihvatljiva sol.
11. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 8, naznačen time što R3 je fluor; ili njegova farmaceutski prihvatljiva sol.
12. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 8, naznačen time što R3 je metoksimetil; ili njegova farmaceutski prihvatljiva sol.
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je {2-[3'-(4-metoksimetilfenil)-2,3,5,6-tetrahidro[1,2']bipirazinil-4-il]etil}metilamid 1-metil-1H-pirazol-4-sulfonske kiseline; ili njegova farmaceutski prihvatljiva sol.
14. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je {2-[3'-(4-hidroksimetilfenil)-2,3,5,6-tetrahidro[1,2']bipirazinil-4-il]etil}metilamid 1-metil-1H-pirazol-4-sulfonske kiseline; ili njegova farmaceutski prihvatljiva sol.
15. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo koji od patentnih zahtjeva 1 do 14 kao aktivni sastojak u smjesi s farmaceutski prihvatljivom podlogom, razrjeđivačem ili pomoćnom tvari.
16. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 14, naznačen time što je namijenjen upotrebi u terapiji.
17. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 14, naznačen time što je namijenjen upotrebi u liječenju migrene kod ljudi.
18. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 14, naznačen time što je namijenjen upotrebi u profilaktičkom liječenju migrene kod ljudi.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96834407P | 2007-08-28 | 2007-08-28 | |
| US4875208P | 2008-04-29 | 2008-04-29 | |
| PCT/US2008/073543 WO2009029439A1 (en) | 2007-08-28 | 2008-08-19 | Substituted piperazinyl pyrazines and pyridines as 5-ht7 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110624T1 true HRP20110624T1 (hr) | 2011-09-30 |
Family
ID=39873874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110624T HRP20110624T1 (hr) | 2007-08-28 | 2011-08-30 | Supstituirani piperazinilpirazini kao antagonisti receptora 5-ht7 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8048884B2 (hr) |
| EP (1) | EP2188268B1 (hr) |
| JP (1) | JP5290293B2 (hr) |
| KR (1) | KR101148616B1 (hr) |
| CN (1) | CN101790522B (hr) |
| AR (1) | AR068111A1 (hr) |
| AT (1) | ATE520673T1 (hr) |
| AU (1) | AU2008293715B2 (hr) |
| BR (1) | BRPI0816468A2 (hr) |
| CA (1) | CA2694911C (hr) |
| CY (1) | CY1111848T1 (hr) |
| DK (1) | DK2188268T3 (hr) |
| EA (1) | EA017809B1 (hr) |
| HR (1) | HRP20110624T1 (hr) |
| MX (1) | MX2010002352A (hr) |
| PE (1) | PE20090629A1 (hr) |
| PL (1) | PL2188268T3 (hr) |
| PT (1) | PT2188268E (hr) |
| SI (1) | SI2188268T1 (hr) |
| TW (1) | TW200914020A (hr) |
| WO (1) | WO2009029439A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI118473B (fi) | 2006-02-17 | 2007-11-30 | Outotec Oyj | Menetelmä kuparin talteenottamiseksi kuparisulfidimalmista |
| CN101821257B (zh) * | 2007-10-12 | 2013-05-22 | 伊莱利利公司 | 5-ht7受体拮抗剂 |
| JP5826822B2 (ja) | 2010-04-16 | 2015-12-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 有害生物防除薬としての新規な複素環化合物 |
| CN103857670B (zh) | 2011-10-11 | 2016-03-23 | Ucb医药有限公司 | 2-氧代-哌啶基衍生物 |
| FR2995605B1 (fr) | 2012-09-18 | 2014-09-19 | Sanofi Sa | Derives de macrolides, leur preparation et leur application therapeutique. |
| EP3083563A1 (en) | 2013-12-20 | 2016-10-26 | Laboratorios Del. Dr. Esteve, S.A. | Piperazine derivatives having multimodal activity against pain |
| US11505529B2 (en) | 2017-03-03 | 2022-11-22 | National Taiwan University | 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome |
| KR102014335B1 (ko) * | 2017-12-01 | 2019-08-26 | 한국과학기술연구원 | 5-ht7 수용체의 조절제로 작용하는 아릴피라졸릴피페라진 또는 아릴피라졸릴다이아제페인의 유도체 및 이를 포함하는 중추신경계 질환 치료 또는 예방용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010102003A (ko) * | 1999-02-10 | 2001-11-15 | 피터 지. 스트링거 | 5-ｈｔ1ｆ 효능제 |
| US20030008880A1 (en) * | 2001-05-02 | 2003-01-09 | Pfizer Inc. | 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity |
| US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
| WO2004067703A2 (en) * | 2003-01-31 | 2004-08-12 | Pfizer Products Inc. | 5ht7 antagonists and inverse agonists |
-
2008
- 2008-08-01 TW TW097129418A patent/TW200914020A/zh unknown
- 2008-08-19 DK DK08798144.5T patent/DK2188268T3/da active
- 2008-08-19 SI SI200830392T patent/SI2188268T1/sl unknown
- 2008-08-19 CA CA2694911A patent/CA2694911C/en not_active Expired - Fee Related
- 2008-08-19 US US12/447,546 patent/US8048884B2/en not_active Expired - Fee Related
- 2008-08-19 AT AT08798144T patent/ATE520673T1/de active
- 2008-08-19 AU AU2008293715A patent/AU2008293715B2/en not_active Ceased
- 2008-08-19 PT PT08798144T patent/PT2188268E/pt unknown
- 2008-08-19 BR BRPI0816468 patent/BRPI0816468A2/pt not_active Application Discontinuation
- 2008-08-19 MX MX2010002352A patent/MX2010002352A/es active IP Right Grant
- 2008-08-19 EA EA201070321A patent/EA017809B1/ru not_active IP Right Cessation
- 2008-08-19 WO PCT/US2008/073543 patent/WO2009029439A1/en active Application Filing
- 2008-08-19 KR KR1020107004378A patent/KR101148616B1/ko not_active IP Right Cessation
- 2008-08-19 PL PL08798144T patent/PL2188268T3/pl unknown
- 2008-08-19 EP EP08798144A patent/EP2188268B1/en not_active Not-in-force
- 2008-08-19 JP JP2010523034A patent/JP5290293B2/ja not_active Expired - Fee Related
- 2008-08-19 CN CN2008801048354A patent/CN101790522B/zh not_active Expired - Fee Related
- 2008-08-27 AR ARP080103721A patent/AR068111A1/es unknown
- 2008-08-27 PE PE2008001449A patent/PE20090629A1/es not_active Application Discontinuation
-
2011
- 2011-08-30 HR HR20110624T patent/HRP20110624T1/hr unknown
- 2011-09-20 CY CY20111100910T patent/CY1111848T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2188268T3 (da) | 2011-10-03 |
| BRPI0816468A2 (pt) | 2015-03-24 |
| EA017809B1 (ru) | 2013-03-29 |
| CN101790522B (zh) | 2012-06-27 |
| KR101148616B1 (ko) | 2012-05-21 |
| WO2009029439A1 (en) | 2009-03-05 |
| PE20090629A1 (es) | 2009-05-16 |
| KR20100038117A (ko) | 2010-04-12 |
| JP2010537994A (ja) | 2010-12-09 |
| PL2188268T3 (pl) | 2011-12-30 |
| PT2188268E (pt) | 2011-10-03 |
| EA201070321A1 (ru) | 2010-08-30 |
| JP5290293B2 (ja) | 2013-09-18 |
| MX2010002352A (es) | 2010-08-04 |
| EP2188268B1 (en) | 2011-08-17 |
| US20100075976A1 (en) | 2010-03-25 |
| AU2008293715B2 (en) | 2013-09-19 |
| AU2008293715A1 (en) | 2009-03-05 |
| AR068111A1 (es) | 2009-11-04 |
| ATE520673T1 (de) | 2011-09-15 |
| CY1111848T1 (el) | 2015-10-07 |
| CA2694911C (en) | 2013-05-07 |
| CN101790522A (zh) | 2010-07-28 |
| CA2694911A1 (en) | 2009-03-05 |
| EP2188268A1 (en) | 2010-05-26 |
| TW200914020A (en) | 2009-04-01 |
| SI2188268T1 (sl) | 2011-11-30 |
| US8048884B2 (en) | 2011-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110624T1 (hr) | Supstituirani piperazinilpirazini kao antagonisti receptora 5-ht7 | |
| KR102488479B1 (ko) | 인플루엔자 바이러스 감염에 사용하기 위한 인돌 | |
| HRP20120830T1 (hr) | Imidazolkarboksamidi | |
| CY1108913T1 (el) | Παραγωγα 4 (φαινυλ-πιπεραζινυλ-μεθυλ) βενζαμιδιου και η χρηση τους για τη θεραπευτικη αντιμετωπιση του πονου, του αγχους ή γαστρεντερικων διαταραχων | |
| HRP20151425T1 (hr) | Inhibitori indazola wnt signalnog puta i njihove terapeutske uporabe | |
| RS54782B1 (sr) | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja | |
| HRP20120505T1 (hr) | Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe | |
| HRP20120257T1 (hr) | Antagonisti receptora 5-ht7 | |
| CY1117638T1 (el) | Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης | |
| RS52865B (en) | Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors | |
| RU2006131304A (ru) | Производные имидазо[1,2-c]пиримидинилуксусной кислоты | |
| EA200901379A1 (ru) | Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа | |
| HRP20191482T1 (hr) | 18f-označeni psma ciljani pet reagensi | |
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| NZ724837A (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
| ME01312B (me) | Heteroaril supstituirani pirol0[2,3-b]piridini i pirol0 [ 2,3-b]pirimidini kao inhibitori janus kinaze | |
| HRP20090208T1 (hr) | Supstituirani derivati pirido[2,3-d]pirimidina korisni kao lijekovi za liječenje autoimunih bolesti | |
| RS51047B (sr) | Derivati 4-tetrazolil-4-fenilpiperidina za lečenje bola | |
| TW200604198A (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| MX2013004588A (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
| EA201170099A1 (ru) | Замещенные пиримидин-4-оновые производные | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| WO2007047793A3 (en) | Cyclopentenol nucleoside compounds, intermediates for their synthesis and methods of treating viral infections | |
| HRP20161237T1 (hr) | Antimalarijski agensi | |
| JP2010537994A5 (hr) |